Allogene Therapeutics (ALLO) Common Equity (2017 - 2026)

Allogene Therapeutics has disclosed Common Equity across 10 years of filings, most recently posting $278.9 million for Q1 2026.

• Common Equity for Q1 2026 came in at $278.9 million, down 27.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $278.9 million (down 27.64% YoY), and the FY2025 annual result was $292.5 million, down 30.71% from the prior year.
• Common Equity came in at $278.9 million for Q1 2026 at Allogene Therapeutics, down from $292.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $865.3 million in Q1 2022 to a low of $278.9 million in Q1 2026.
• The 5-year median for Common Equity is $512.2 million (2023), against an average of $521.6 million.
• Peak annual rise in Common Equity reached 16.47% in 2025, while the deepest fall reached 33.1% in 2025.
• Allogene Therapeutics' Common Equity stood at $666.9 million in 2022, then retreated by 23.19% to $512.2 million in 2023, then retreated by 17.58% to $422.2 million in 2024, then slumped by 30.71% to $292.5 million in 2025, then declined by 4.67% to $278.9 million in 2026.
• The last three Common Equity figures came in at $278.9 million (Q1 2026), $292.5 million (Q4 2025), and $315.3 million (Q3 2025), per Business Quant data.